DFTX catalyst calendar

Definium Therapeutics, Inc.

Upcoming catalysts
3
Cash runway
76.3 months
Cash & investments
$1084M
Phase 3 programs
4

Definium Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Medicinal Chemicals & Botanical Products.

The next scheduled catalyst is Next quarterly earnings (projected) on December 18, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.

Cash runway is approximately 76.3 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Upcoming catalysts

DateEventTypePhase
December 18, 2026 est. Next quarterly earnings (projected) Earnings —
August 15, 2027 A Phase 2A Trial of DT402 for Autism Spectrum Disorder Trial Milestone Phase 2
September 15, 2027 A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) Trial Milestone Phase 3

Track DFTX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open DFTX in the tracker

Recent history

DateEventTypePhase
September 14, 2026 8-K filed: Reg FD disclosure, Other event Filing —
September 8, 2026 8-K filed: Other event Filing —
August 13, 2026 A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) Trial Milestone Phase 3
August 12, 2026 8-K filed: Reg FD disclosure, Other event Filing —
August 6, 2026 Quarterly results filed (8-K) Earnings —
July 15, 2026 A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage) Trial Milestone Phase 3
June 24, 2026 8-K filed: Material agreement, Other event Corporate —
June 22, 2026 8-K filed: Reg FD disclosure, Other event Filing —
June 12, 2026 8-K filed: Leadership change Corporate —
May 20, 2026 A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge) Trial Milestone Phase 3
May 19, 2026 8-K filed: Other event Filing —
May 12, 2026 8-K filed: Other event Filing —
May 7, 2026 Quarterly results filed (8-K) Earnings —
April 22, 2026 8-K filed: Other event Filing —
February 26, 2026 Quarterly results filed (8-K) Earnings —
January 29, 2026 8-K filed: Leadership change Corporate —
January 12, 2026 Quarterly results filed (8-K) Earnings —
November 6, 2025 Quarterly results filed (8-K) Earnings —
October 31, 2025 8-K filed: Material agreement, Other event Corporate —
October 29, 2025 Quarterly results filed (8-K) Earnings —
September 4, 2025 8-K filed: Other event Filing —
July 31, 2025 Quarterly results filed (8-K) Earnings —
June 16, 2025 8-K filed: Leadership change Corporate —
May 27, 2025 8-K filed: Leadership change, Reg FD disclosure Corporate —
May 8, 2025 Quarterly results filed (8-K) Earnings —
April 21, 2025 8-K filed: Material agreement Corporate —
April 15, 2025 8-K filed: Other event Filing —
November 6, 2023 Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial Trial Milestone Phase 2
October 6, 2023 A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms Trial Milestone Phase 2
December 13, 2021 A Study to Assess 18-Methoxycoronaridine (18-MC HCl) in Healthy Volunteers Trial Milestone Phase 1

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.